Compare AOSL & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AOSL | IOVA |
|---|---|---|
| Founded | 2000 | 2007 |
| Country | United States | United States |
| Employees | N/A | 838 |
| Industry | Semiconductors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 940.9M | 881.3M |
| IPO Year | 2010 | N/A |
| Metric | AOSL | IOVA |
|---|---|---|
| Price | $22.57 | $2.33 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 12 |
| Target Price | ★ $24.33 | $10.45 |
| AVG Volume (30 Days) | 308.9K | ★ 12.5M |
| Earning Date | 02-05-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $696,776,000.00 | $250,425,000.00 |
| Revenue This Year | N/A | $60.71 |
| Revenue Next Year | $6.59 | $59.52 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 5.81 | ★ 175.62 |
| 52 Week Low | $15.90 | $1.64 |
| 52 Week High | $46.65 | $6.50 |
| Indicator | AOSL | IOVA |
|---|---|---|
| Relative Strength Index (RSI) | 61.53 | 45.76 |
| Support Level | $21.86 | $2.21 |
| Resistance Level | $22.56 | $2.80 |
| Average True Range (ATR) | 0.70 | 0.18 |
| MACD | 0.22 | -0.05 |
| Stochastic Oscillator | 77.84 | 20.74 |
Alpha & Omega Semiconductor Ltd designs, develops and supplies a portfolio of power semiconductors targeting various applications, including personal computers, flat-panel TVs, LED lighting, smartphones, battery packs, consumer and industrial motor controls and power supplies for TVs, computers, servers and telecommunications equipment. It generates revenue mainly from the sale of power semiconductors, consisting of power discretes and power ICs with a presence in Hong Kong, China, South Korea, the United States and other countries. It operates in one operating segment: the design, development and supply of power semiconductor products for computing, consumer electronics, communication and industrial applications.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.